RecruitingPhase 2

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

United States20 participantsStarted 2023-05-25

Plain-language summary

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

What they're measuring

Complete Remission (CR)

Timeframe: Day 29

Complete Remission (CR)

Timeframe: Day 64

Complete Response with Partial Count Recovery (CRh)

Timeframe: Day 29

Complete Response with Partial Count Recovery (CRh)

Timeframe: Day 64

Complete Remission incomplete (CRi)

Timeframe: Day 29

Complete Remission incomplete (CRi)

Timeframe: Day 64

Minimal Residual Disease Negativity (MRD-)

Timeframe: Day 29

Minimal Residual Disease Negativity (MRD-)

Timeframe: Day 64

Morphologic Relapse

Trial details

NCT IDNCT05289687

SponsorEastern Cooperative Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2027-06-30

Contact for this trial

Shira Dinner, MD

312-695-6180 shira.dinner@nm.org

View on ClinicalTrials.gov More T-cell Acute Lymphoblastic Leukemia trials